Search 

Arcinova offers a full suite of drug substance, drug product and analytical support services from preclinical through to small scale commercial. We have a big company track record and compliance (ex-Sanofi, Covance) coupled with the responsiveness and agility of a smaller company. We also partner with Covance to deliver fully integrated solutions.

Our legacy customer base has now grown to over 116 since we bought our site in Alnwick, Northumberland, UK from Covance in February 2016 and rebranded as Arcinova. We are very keen to meet new partners and help them progress their candidates into the clinic and through trials.

Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA.

CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.

With over 20 years’ experience on more than 650 projects, CNS is one of the most experienced providers within the market and a partner of choice for biotech companies.

Oncology specialised contract clinical research company providing flexible, customised, bespoke clinical development planning and clinical trial design & execution services to the pharmaceutical and biotechnology industries. Although specialised in oncology, we also have experience in many other therapeutic areas, and have a sister company Karma Cardiology providing the same, flexible, customised services in cardiology & cardiovascular disease.

Selcia Ltd is a leading provider of contract research and innovation services in Drug Discovery and 14C Radiolabelling.

Selcia Drug Discovery provides the medicinal chemistry and biology expertise and resource to accelerate your early phase drug discovery project and deliver robust preclinical candidates. Our highly experienced project managers and scientists provide innovative solutions which have resulted in co-authorship on over 30 customer patents and publications and delivery of 11 preclinical candidates, with 2 due in the clinic this year. We have also been successful in supporting biotechs in raising a total of £8 million through various bodies to fund drug discovery endeavours.

In January 2018 Selcia became part of Eurofins Pharma Discovery Services affording Selcia the capacity to deliver extensive and seamless solutions and services that span the whole spectrum of drug discovery.